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Abstract
Background: Antisynthetase syndrome is a rare and debilitating multiorgan disease characterized by inflammatory
myopathy, interstitial lung disease, cutaneous involvement, and frequent chronic inflammation of the joints.
Standard treatments include corticosteroids and immunosuppressants. In some cases, treatment resistance may
develop. Administration of immunoglobulins intravenously is recommended in patients with drug-resistant
antisynthetase syndrome.
Case presentation: Here, we describe the case of a 56-year-old woman of Algerian origin. She is the first case of
a patient with multidrug-resistant antisynthetase syndrome featuring pulmonary involvement and arthropathy, and
chronic secondary immune deficiency with recurrent infections, after anti-CD20 treatment, in which her primary
antisynthetase syndrome-related symptoms and secondary immune deficiency were treated successfully with
subcutaneous administration of immunoglobulin. The administration of immunoglobulin subcutaneously was
introduced at a dose of 2 g/kg per month and was well tolerated. Clinical improvement was observed within
3 months of initiation of subcutaneous administration of immunoglobulin. After 22 months of treatment, she showed
a significant improvement in terms of muscle strength, pulmonary involvement, arthralgia, and immunodeficiency.
Her serum creatine phosphokinase and C-reactive protein levels remained normal. Finally, she was compliant and
entirely satisfied with the treatment.
Conclusions: Taken together, these observations suggest that administration of immunoglobulin subcutaneously may
be a useful therapeutic approach to tackle steroid-refractory antisynthetase syndrome while ensuring minimal side
effects and improved treatment compliance. This treatment also allowed, in our case, for the regression of the chronic
immunodeficiency secondary to rituximab treatment.
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Background
Antisynthetase syndrome (aSS) is a rare idiopathic auto-
immune condition occurring in a subgroup of patients
with polymyositis and dermatomyositis who are positive
for one or several of eight anti-aminoacyl transfer ribo-
nucleic acid (RNA) synthetase (ARS) auto-antibodies [1].
Six major clinical hallmarks define the syndrome: fever,
myositis, interstitial lung disease, “mechanic’s hands”, Ray-
naud phenomenon, and inflammatory polyarthritis [2].
Symptoms may occur individually or in a variety of com-
binations; hence, a straightforward diagnosis is challenging
[3, 4]. Of interest, there is evidence that the clinical picture
and outcome of aSS are intimately tied to the identity of
the ARS antibody being expressed [5, 6]. The most com-
mon form of aSS is anti-Jo-1 antibody-associated (anti-
histidyl-transfer RNA synthetase) and features polymyosi-
tis of proximal muscles alongside interstitial lung disease
or, rarely, pulmonary hypertension [7–9].
Due to multiorgan involvement, aSS is a debilitating con-
dition associated with increased morbidity and mortality,
especially when pulmonary function is affected [10, 11].
Moreover, myocardial complications and malignancies may
also occasionally be observed within this patient popula-
tion and contribute to poor prognosis [12–14].
Currently, glucocorticoids are the mainstay of therapy
and may be completed by immunosuppressive treatments,
typically methotrexate (MTX) or azathioprine, in order to
decrease steroid dose and to achieve disease control
[15–17]. Cyclophosphamide can be used to control inter-
stitial lung disease. In treatment-refractory patients, rituxi-
mab (RTX) may also be considered [18, 19]. Because of the
low prevalence of aSS, there is a lack of randomized con-
trolled trials comparing the efficacy and safety of different
treatment approaches. However, a few studies supported
administration of immunoglobulins intravenously (IVIg) as
a promising therapeutic avenue for treatment-refractory
patients, or those wishing to avoid the risks associated with
chronic corticosteroid exposure [16, 20–23]. More re-
cently, high-dose administration of immunoglobulin sub-
cutaneously (SCIg) has arisen as a less invasive and more
economical alternative to IVIg [20, 24, 25].
Here, we report the case of a patient with aSS, refrac-
tory to steroid and immunosuppressive treatment, and
poorly tolerating both RTX and IVIg. She developed
secondary chronic immune deficiency with recurrent
infections after anti-CD20 (RTX) treatment. In this pa-
tient, a combined SCIg and MTX treatment significantly
improved her aSS-specific symptoms and overall health
status which, in addition, enabled the disappearance of
secondary immune deficiency.
Case presentation
A 56-year-old woman, 70 kg, of Algerian origin was
referred to us in August 2003 presenting with fatigue,
proximal and bilateral muscular weakness (muscle test-
ing score of 69 points compared to a score of 88 in
healthy individuals), apprehension to grasp, and difficul-
ties in getting dressed. Additional symptoms included
effort dyspnea, swollen hands, and purple erythema of
her eyelids. Appendicitis, sciatica, tachycardia, hyperten-
sion, and asthma were listed in her medical history. Her
creatine phosphokinase (CPK, muscle enzymes) levels
were six times the normal (N) level. Auto-antibodies
measurements were initially not performed.
A muscle biopsy was performed, and showed character-
istic patterns of dermatomyositis with perifascicular atro-
phy, evidence of injury to capillaries and perifascicular
myofibers, and inflammatory infiltrates in the perimysial
region (predominantly CD4+). She was diagnosed as hav-
ing dermatomyositis in November 2003 and prednisone
treatment (1 mg/kg per day) was initiated. A repeated
search for malignancy was negative. A diagnosis of a mild
interstitial pneumonitis together with the presence of
anti-Jo1 antibodies further confirmed the suspicion of aSS.
Her gamma globulin levels were normal.
Since treatment response was incomplete, immunosup-
pressant therapy with azathioprine (2 mg/kg per day),
which was replaced after 9 months by MTX (15 mg per
week), was introduced. However, both were poorly toler-
ated and she developed cytopenia. Therefore, infusions
with IVIg (2 g/kg per month) were initiated for six
months, in addition to steroids.
In September 2006, due to lack of response to these
different therapies, RTX (2 g every 6 months) was intro-
duced and our patient reported an improvement in her
articular and muscular pain. Yet, because of the develop-
ment of hypogammaglobulinemia, RTX was discontin-
ued in October 2011. Of importance, no immune deficit
had been present prior to the introduction of RTX.
She was readmitted in December 2012 with a muscle
weakness score of 75.5 points (over 88 points in healthy
individuals) [21]. Her CPK levels were normal, but
probing for anti-Jo-1 antibody was positive. In addition, a
lung scan revealed the presence of interstitial basal lung
infiltrate (Fig. 1). Testing of pulmonary function showed a
reduction of single-breath diffusion capacity for carbon
monoxide (DLCO; 48%), with a total lung capacity (TLC)
of 72%, and forced expiratory volume in 1 second (FEV1)/
vital capacity (VC) at 73%. A slight muscle inflammation
of her thighs was also evidenced by magnetic resonance
imaging (MRI). In terms of treatment strategy, a bolus in-
jection of IVIg (2 g/kg) was administered, but she devel-
oped adverse effects, including headache and distal
paresthesia, after which she refused to receive another
IVIg infusion. Her treatment adherence was poor and
in addition to refusing to try a different IVIg formula-
tion, she had also resumed the corticosteroid treat-
ment in November 2012. In fact, she expressed
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wishes against hospitalizations and stopped all the
treatments.
An immunologic evaluation showed hypogammaglo-
bulinemia (4.4 g/l), with reduced total immunoglobu-
lin G (IgG) (4.2 g/l), and a reduction in each subclass
of IgG: IgG1 2.48 g/l (N >3.82 g/l), IgG2 1.65 g/l (N
>2.41), IgG3 0.14 g/l (N >0.2), and IgG4 0.038 g/l (N
>0.18 g/l). Her IgA (0.5 g/l, N >0.7) and IgM levels
(0.34 g/l, N >0.4) were also decreased. Her IgE levels
were normal.
She was seen again in May 2014, when her general
health had deteriorated due to the discontinuation of
steroids, RTX, and IgG treatment. In particular, she
complained about severe fatigue and presented with
swelling of the proximal interphalangeal joints of her
right index and middle finger. An MRI scan of her right
hand revealed an advanced and destructive arthropathy
associated with significant synovitis of the proximal in-
terphalangeal joints of the first, second, and third rays
and, to a lesser extent, of the fourth and fifth rays (Fig. 2).
Her metacarpal phalangeal joints were not affected, but
an erosive synovitis of the dorsal scapholunate articula-
tion and beginning erosion of the lunate were observed.
Her radioulnar joint was not affected.
At this point, her muscle weakness score was 70/88,
with a muscle strength of +3 as measured bilaterally at
her middle trapezius, major gluteal, and psoas muscles.
Her muscle disability was rated 18/75 (score ranging
from 0 no disability to 75 maximum disability) [22]. An
MRI of her thighs did not reveal any significant evolu-
tion of myopathy since the previous examination in
2012. In particular, there was no important inflammatory
signal of the muscle and no sign of amyotrophy.
Likewise, a thorax scan confirmed the stabilization of
the abnormalities reported in November 2012, with
mostly the basal regions being affected. Pulmonary
function testing was also indicative of overall stability
compared to 2012: single-breath DLCO was 46%, TLC
70%, and FEV1/VC 73%. Whereas DLCO, TLC (−30%),
and functional respiratory deficit (25%) were un-
changed, a slight decrease of forced expiratory flow
(FEF)25–75 was noted.
Of importance, she complained of frequent infections
of the upper airways, including pharyngitis, sinusitis,
bronchitis, and otitis for the past 2 years. Consistent
with these recurrent infections, an immunologic evalu-
ation confirmed a persistent hypogammaglobulinemia
(5.0 g/l), with reduced total IgG (4.1 g/l), and reduction
of each subclass of IgG: IgG1 2.3 g/l, IgG2 1.48 g/l, IgG3
0.11 g/l, and IgG4 0.04 g/l. This picture was evocative of
a persistent common variable immunodeficiency (CVID)
secondary to RTX. Her C-reactive protein (CRP) level
was 22.7 mg/l and her CPK level was 489 UI/l.
Treatment with Gammanorm® (SCIg) was initiated
in July 2014 (2 g/kg per month divided into two infu-
sions per week). After 3 and 6 months, respectively,
of treatment, she reported diffuse pain, which was
present since discontinuation of Cortancyl® (prednis-
one), and general fatigue. Arthritis of her proximal
and metacarpal phalangeal joints was still present, but
her muscle weakness score had improved to 75/88
and muscle disability was rated 12/75 [22]. Of
importance, no novel infectious episode was reported.
In fact, Gammanorm® (SCIg) was well tolerated and
she confirmed a slight improvement in her general
health state.
Fig. 1 Lung scan showing the presence of interstitial basal lung infiltrate
Fig. 2 Magnetic resonance imaging scanner of the right hand showing
an advanced and destructive arthropathy associated with significant
synovitis of the proximal interphalangeal joints of the first, second, and
third rays and, to a lesser extent, of the fourth and fifth rays
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In January 2015, MTX (15 mg/week) was reintroduced
and a significant clinical improvement was achieved by
April. Notably, her serum CRP (3.3 mg/l) and CPK (63
UI/l) returned to normalized levels despite persisting fa-
tigue, along with arthritis of her metacarpal and proximal
interphalangeal joints (arthritis confirmed at a consult-
ation in May 2015). Nevertheless, the normalization of
her immunodeficiency and the significant improvement in
the state of her general health remained stable, as reas-
sessed in November 2015.
Finally, in May 2016, joint manifestations had disap-
peared and fatigue had regressed significantly. No infec-
tion had been observed during the past 18 months. Her
muscle weakness score had also improved to 82/88 and
muscle disability was rated 9/75. Her CRP and CPK
levels were normal. As shown by immunologic evalu-
ation, hypogammaglobulinemia had resolved and all
subclasses of IgG were normalized.
Moreover, the results of a thorax scan indicated a slight
improvement in basal lung infiltrate, alongside pulmonary
function testing: DLCO of 55%, TLC of 75%, and a FEV1/
VC 74%.
Discussion
To the best of our knowledge, this is the first report of a
case of aSS pathology with concomitant secondary im-
mune deficiency secondary to RTX, successfully treated
with SCIg. Of importance, and in addition to a progres-
sive improvement of aSS-related symptoms, our patient
fully recovered from RTX-induced immune deficiency,
tolerated SCIg treatment very well, and reported a sub-
stantial increase in her quality of life. Hence, SCIg
emerges as a safe, efficient, and patient-friendly alter-
native for the treatment of this rare, complex, and
burdensome form of polymyositis.
Although rare, aSS is a challenging pathology because
of the complexity and severity of symptoms [3, 4], some
of which are highly debilitating and/or life threatening
[10–13]. Unfortunately, the most common therapeutic
avenue – corticoid treatment – is jeopardized by side
effects and the development of treatment resistance. In
the present case, a first-line corticoid therapy did not
achieve satisfactory disease control. Conversely, a num-
ber of second-line treatments, including immunosup-
pressant therapy (azathioprine, MTX, RTX) and IVIg,
although somewhat efficient in terms of symptomatology
were poorly tolerated by the patient. Notably, anti-CD20
immunosuppressant therapy provoked a persistent
immunodeficiency, including hypogammaglobulinemia.
Due to the recurrence of heavy side effects combined
with poor therapeutic efficacy, our patient’s compliance
with the treatment degraded and she became reluctant
to try alternative approaches (for instance, different IVIg
formulations) [26, 27].
Under the double burden of an untreated aSS and a
persistent immune deficiency, our patient’s general
health dramatically deteriorated. In this precarious
situation, the introduction of SCIg (2 g/kg per month)
proved to be efficacious in eradicating the immune defi-
ciency and progressively downscaling aSS-related symp-
toms. In fact, 6 months into the treatment, her immune
function had recovered, as proven by the absence of
new infectious episodes and the normalization of her
IgG and CRP levels. Her pulmonary and muscle func-
tion had also improved and her CPK normalized. In
addition, the general improvement in her health en-
abled resumption of her MTX treatment, and eventu-
ally led to full disease control, including alleviation of
arthropathy, regression of fatigue, and a substantial
increase in quality of life within less than 12 months
of SCIg initiation.
We believe that this double action of SCIg on
stabilization of immune function and aSS disease man-
agement is of particular interest in the light of several
recent reports featuring the prolonged effects of RTX on
the immune system. In fact, in their retrospective chart
review, Kaplan et al. identified a subset of patients re-
ceiving RTX treatment and presenting with prolonged
immune suppression, which required immunoglobulin
replacement therapy even after discontinuation of anti-
CD20 treatment [28].
Likewise, Levy et al. report in their retrospective
analysis of 32 studies conducted in France between 2001
and 2014 three cases of prolonged hypogammaglobuli-
nemia in patients who had received RTX as a second-
line treatment for immune thrombocytopenia [29]. Of
interest, the clinical picture was reminiscent of CVID,
including recurrent infections, and lasted up to 2 years
after RTX discontinuation. A further analysis of the
literature allowed the authors to conclude that severe
hypogammaglobulinemia is a rare but severe and long-
lasting side effect of RTX treatment. These reports,
together with our case, call for caution and the close
monitoring of immune function in patients who receive
RTX for the treatment of autoimmune disorders.
In addition to proving efficient at tackling both aSS
pathology and secondary immunodeficiency, SCIg was
also particularly well tolerated in the present case. Given
the poor tolerance of a variety of previous therapies and
our patient’s growing opposition to treatment, this
represents a chief clinical benefit. Our observations are
consistent with previous reports, indicating that the
subcutaneous route of Ig administration is generally
better tolerated than the systemic one [30]. Another
crucial advantage of the SCIg formulation over IVIg
is of course the ease of administration, which allows
for home-based use and thereby reduces costly hospi-
talizations, while increasing patient autonomy [31].
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Conclusions
In summary, the case reported here supports SCIg as an
efficient and safe alternative, which is more economical
than IVIg, for the treatment of complex and/or refractory
forms of aSS. Of importance, in this particular case, the
clinical benefit of SCIg went beyond the control of pri-
mary aSS-related symptoms, since a secondary immune
deficiency was also successfully treated. In the light of
these promising outcomes, we believe that SCIg should
also be considered a valuable tool for the management of
other autoimmune conditions.
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